P2X3 receptor antagonist in chronic cough – Authors' reply
John A. Smith(Cleveland Metropolitan School District), Anthony Ford(Sunesis (United States)), Kimberley Holt(Manchester Academic Health Science Centre), Gary Layton(University of Geneva), Rachel Dockry(Manchester Academic Health Science Centre), Bruce G. McCarthy, Rayid Abdulqawi(Alfaisal University)
Cited by 1
Related Papers
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2014|488
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension
|Circulation|2011|375
Anatomy and Neurophysiology of Cough
|CHEST Journal|2014|283
Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension
|CHEST Journal|2011|257
A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
|Nature Communications|2020|245